Desmoplastic/nodular medulloblastoma

Desmoplastic/nodular medulloblastoma (DNM) is a specific histological variant of medulloblastoma, a malignant embryonal tumor of the cerebellum (posterior fossa of the brain). Classified under ICD-10 code C71.6 (malignant neoplasm of the cerebellum), this variant is characterized by nodular, reticulin-free zones (pale islands) surrounded by densely packed, highly proliferative desmoplastic (collagen-rich) internodular regions. It accounts for a notable proportion of medulloblastomas, particularly in infants and young adults, and is generally associated with a more favorable prognosis compared to classic or large cell/anaplastic medulloblastoma variants. Desmoplastic/nodular medulloblastoma primarily affects the central nervous system, specifically arising in the cerebellar hemispheres rather than the midline vermis, which is more typical of classic medulloblastoma. Patients commonly present with symptoms of increased intracranial pressure due to obstruction of cerebrospinal fluid flow, including headaches, nausea, vomiting, and balance or coordination difficulties (ataxia). In infants, a bulging fontanelle and increasing head circumference may be observed. Some cases are associated with Gorlin syndrome (nevoid basal cell carcinoma syndrome), which involves germline mutations in the PTCH1 gene on chromosome 9q22, linking this variant to aberrant Hedgehog signaling pathway activation. Treatment typically involves maximal safe surgical resection of the tumor, often followed by risk-adapted chemotherapy and, in older children and adults, craniospinal radiation therapy. In infants, chemotherapy-only approaches are often preferred to avoid the neurodevelopmental toxicity of radiation. The desmoplastic/nodular variant, particularly when occurring in infants, has been associated with significantly better outcomes compared to other medulloblastoma subtypes, with higher rates of long-term survival. Molecularly, most desmoplastic/nodular medulloblastomas fall within the SHH (Sonic Hedgehog) molecular subgroup, which has implications for targeted therapeutic strategies currently under investigation.

Common questions about Desmoplastic/nodular medulloblastoma